Novartis hopes to prevent, treat and block malaria and is conducting clinical trials to test some promising therapies. Learn more.

Dr. Botond Roska says we should keep our eyes on gene therapy.

Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.

A Novartis experimental drug in clinical trial aims to block liver cancer growth

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.

Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.

Ann Aerts has stared death in the eye. The head of the non-profit Novartis Foundation lost colleagues when she was serving as an emergency medicine physician on a medical mission in a dangerously unstable country.

After 40 years of working in information technology, Jim Barrington took a partial retirement from his job as Novartis’ chief information officer and started looking for new ways to apply his skills.